Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system. (PubMed, Front Immunol) - Sep 25, 2026 - "Among all ICIs, nivolumab had the greatest number of ICI-TD reports (a = 655, 32.73% of all 2,001 reports, ROR025 = 2.97, IC025 = 1.32, PRR = 3.21, χ2 = 782.34)...The present study provided a comprehensive overview of the demographic features of patients and pharmacovigilance signal patterns of ICI-TD during the treatment of lung cancer. Our findings would offer a referential perspective for the clinical understanding of the pharmacovigilance signals of ICI-TD."
Adverse events • Checkpoint inhibition • Journal • Endocrine Disorders • Lung Cancer • Oncology • Solid Tumor
|